Prometheus, Bayer Schering in Cancer PGx Pact

Prometheus will develop diagnostic pathway technologies for Bayer Schering Pharma's cancer drug candidates under a deal which could bring in up to $160 million to Prometheus.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.